Critical Updates in TP53 MDS Prognosis: 2025 Findings Check out our extensive video library (see channel for our latest videos) Introduction TP53 MDS prognosis remains one of the most challenging aspects of myeloid malignancies, with survival outcomes dramatically worse than other genetic
Tag: AML
Venetoclax-based Regimens in AML: The New Standard or a Temporary Fix?
Venetoclax-based Regimens in AML: The New Standard or a Temporary Fix? Abstract Acute myeloid leukemia (AML) remains a challenging hematologic malignancy, particularly among older adults and patients unfit for intensive chemotherapy. Over the past decade, treatment models have shifted with the advent of venetoclax, a selective BCL-2 inhibitor,
